Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ligand Pharmaceuticals Inc announces successful first-in-human trial results for Glucagon Program

Monday, 16 Jun 2014 08:00am EDT 

Ligand Pharmaceuticals Inc:Data from Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate robust response on fasting plasma glucose after a single dose.LGD-6972 was well-tolerated; there were no clinically significant or dose-dependent changes in hematology, clinical chemistry, urinalysis, ECG or vital signs, and no serious adverse events.LGD-6972 was well-absorbed after oral administration; peak plasma concentrations were reached approximately 5 to 8 hours post dose with a long elimination half-life of about 50 hours, supporting once-daily dosing.After a single dose, LGD-6972 reduced fasting plasma glucose in normal healthy volunteers and in subjects with type 2 diabetes.Fasting plasma glucose was reduced by 57 mg/dL (placebo-adjusted) in subjects with type 2 diabetes, suggesting a robust response in this acute study. 

Company Quote

0.89 +1.02%
4:00pm EDT